Research
Pemetrexed in Children with Recurrent Cancer
Protocol Description
This Phase II multi-center study explores how pemetrexed disodium works in treating young patients with solid tumors that have relapsed or not responded to treatment. Pemetrexed disodium may stop the growth of tumor cells by blocking the cancer cells in the body from using folate, a naturally occurring vitamin that is found in many of the foods we eat and is used by the body to keep normal cells growing. Information gathered from this research will facilitate understanding of the efficacy of this drug in recurrent tumors.
Eligibility Criteria
Patients of both genders diagnosed with a recurrent or progressive solid tumor that have been unable to be cured by any known standard treatment will be eligible to participate.
Males: Up to age 22
Females: Up to age 22
Requirements
Patients receive pemetrexed disodium intravenously once every 21 days for up to 17 courses. Additional drugs, which will include dexamethasone, Vitamin B12 and a multivitamin, will be a required portion of the treatment plan and administered either orally or by injection. Patients may receive this course of treatment for up to a year.
Frequency of visits: Weekly
Duration: Up to 1 year of treatment
Status: Enrollment Closed
Sources of Support
Children’s Oncology Group
National Cancer Institute
Eli Lilly and Company
Additional Resources
Study description at National Institutes of Health
Children’s Oncology Group CureSearch
National Cancer Institute
Primary Investigator(s)
Regina Jakacki, MD
Contact Information
To get started, please contact:
Sharon DiBridge, CRA
412-692-7070
Angela Krol, Research RN, BSN
412-692-8047
